Please assess the completion status of the following clinical trial:

Trial Title: Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Has diabetes mellitus with symptoms of gastroparesis and previously documented gastric emptying delay or previously documented idiopathic gastroparesis in the last 5 years.~2. Has a body mass index (BMI) greater than or equal to (\>=) 16 and less than or equal to (\<=) 40 kilogram per square meter (kg/m\^2) at the Screening Visit.~Exclusion Criteria:~1. Has glycosylated hemoglobin (HbA1c) greater than (\>) 12 percent (%).~2. Has other structural diseases/conditions that affect the gastrointestinal (GI) system.~3. Are unable to withdraw drugs known to alter GI transit 48 hours prior to the study.~4. Has clinically significant abnormal baseline safety laboratory values.~5. Has preexisting hepatic disease that meets Child-Pugh Class B (moderate; total score 7 to 9 points) or C (severe; total score 10 to 15 points).~6. Are without known preexisting hepatic disease who have 1 or more of the following:~   * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2 times the upper limit of normal (ULN).~  * Bilirubin \>1.5 times the ULN unless due to Gilbert's syndrome.~  * International normalized ratio (INR) \>1.5 unless on anticoagulation therapy.~7. Has QT intervals with Fridericia correction method (QTcF) interval (\>=) 460 millisecond (msec) or with other factors that increase the risk of QT prolongation or arrhythmic events at screening. Note: Participants with bundle branch block and a prolonged QTc interval, or with QTcF between 450 and 460 msec, should be reviewed by the Medical Monitor for potential inclusion.~8. Has second or third degree atrioventricular (AV) block; AV disassociation; \>5 beats of non-sustained VT at a rate \>120 beats per minute (bpm); Electrocardiogram (ECG) changes consistent with acute myocardial ischemia or infarction.~9. Has cardiac history that includes conditions requiring heart rate control (example, atrial fibrillation, atrial flutter, ventricular tachycardia, or other tachyarrhythmias).~10. Has clinical evidence (including physical examination, ECG, clinical laboratory value and review of the medical history) of significant cardiovascular, respiratory, moderate or severe renal insufficiency (creatinine clearance \<=60 mL/min), hematological, neurological, or psychiatric disease, or other disease that interferes with the objectives of the study.~11. If female, are pregnant or lactating or intending to become pregnant before participating in this study, during the study, and 4 to 5 days (5 half-lives) PLUS 30 days after last dose of the study drug; or intending to donate ova during such time period.~12. Are considered by the investigator to be alcoholics not in remission or known substance abusers. Have a history of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to: beer \[354 milliliter per \[mL/\] 12 ounces\], wine \[118 mL/4 ounces\], or distilled spirits \[29.5 mL/1 ounce\] per day).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): TAK-954 placebo-matching, 60-minute infusion, intravenously (IV), once daily on Days 1 to 3.
- TAK-954 0.1 mg (Type: EXPERIMENTAL): TAK-954 0.1 mg, 60-minute infusion, IV, once daily on Days 1 to 3.
- TAK-954 0.3 mg (Type: EXPERIMENTAL): TAK-954 1 mg, 60-minute infusion, IV, once daily for up to 3 days.
- TAK-954 1 mg (Type: EXPERIMENTAL): TAK-954 1 mg, 60-minute infusion, IV, once daily on Days 1 to 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).